Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

LANADELUMAB vs LAPATINIB DITOSYLATE: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

LANADELUMAB vs LAPATINIB DITOSYLATE: Safety Overview

Metric LANADELUMAB LAPATINIB DITOSYLATE
Total FAERS Reports 2,058 3,948
Deaths Reported 109 921
Death Rate 5.3% 23.3%
Hospitalizations 1,007 752
Average Patient Age 47.3 yrs 57.3 yrs
% Female Patients 75.7% 95.0%
FDA Approval Date N/A Aug 16, 2024
Manufacturer Takeda Pharmaceuticals America, Inc. AvKARE
Route SUBCUTANEOUS ORAL
Marketing Status N/A Prescription